VPT:CC - Ventripoint Welcomes Dr. Howard Michael Leong-Poi as New Clinical Advisor
(TheNewswire)
Toronto, Ontario – TheNewswire –April 19, 2022 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased to have Dr. Howard Michael Leong-Poijoin the Board of Clinical Advisors.
Dr. Howard Leong-Poi is Head of the Division ofCardiology, as well as the Medical Director of the Heart and VascularProgram at St. Michael’s Hospital in Toronto, Ontario. He is also aFull Professor of Medicine at the University of Toronto. He iscurrently an Associate Editor for the Canadian Journal of Cardiologyand has published over 100 articles in peer-reviewed journals. Dr.Leong-Poi has served on multiple grant review panels, such as theCancerCare Manitoba Foundation, Swiss National Science Foundation,Canadian Foundation for Innovation, and others. He is a member of theInstitute of Medical Sciences, Canadian Society of Echocardiography,Canadian Cardiovascular Society, and other notable associations. Dr.Leong-Poi has received numerous international awards, including the2017 Feigenbaum Lecturer, recipient of the 2005 William W. ParmleyYoung Author Achievement Award, and 1st prize for the Research AwardCompetition for the American Society of Echocardiography.
Dr. Leong-Poi’s clinical research interests focus oncardiac imaging, specifically echocardiography, in coronary arterydisease, heart failure and valvular heart disease. His extensiveexperience and clinical research will bring insight and ideas for thedevelopment of the VMS+ system to better diagnose and monitorcardiovascular disease.
“I am very pleased to join the Ventripoint team as aclinical advisor, as I believe that the AI technology Ventripoint hasdeveloped and continues to improve is the way forward to providingbetter diagnostic accuracy and ultimately improving care to ourpatients.” Stated Dr. Leong-Poi.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Mr. John Grosso
Mr. Cory Bataan
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2022 TheNewswire - All rights reserved.